Bundle BCU People Committee 12 January 2024

 14:00 - PC24/1 Welcome, introduction to Committee and apologies for absence
 PC24/2 Review of the Terms of Reference for the People Committee Chief Executive / Acting Board Secretary Recommendation The Committee is asked to: Review and Endorse the draft Terms of Reference PC24.2a ToR People Committee v2 PC24.2b People Committee ToR v0.02 Draft (reviewed 11.12.23 - untracked version 04.01.24)
 PC24/3 Developing a Cycle of Business for the People Committee Chief Executive / Acting Board Secretary Recommendation The Committee is asked to:

 Discuss the forward programme for this Committee.
 Consider a Cycle of Business for the next 12 months PC24.3a COB People Committee v3

PC24.3b App1 People Committee CoB 2024-25 v0.02 Draft

4 15:30 - PC24/4 Date of next meeting



Teitl adroddiad:	A Deview of the Terme of Defense of fer the Deview of Committee					
Report title:	A Review of the Terms of Reference for the People Committee					
Adrodd i:						
Poport to:	People Committee					
<i>Report to:</i> Dyddiad y Cyfarfod:						
	Friday, 12 January 2024					
Date of Meeting: Crynodeb	The purpose of this report is to provide the People Committee with a					
Gweithredol:	proposed Terms of Reference for review and endorsement .					
Evenutive Summery	proposed remits of Reference for review and endorsement.					
Executive Summary:						
	As reported at the Health Board on 28 September 2023, one of the key					
	Special Measures deliverables includes the requirement to "Establish					
	/Re-establish Board Committees" and it was agreed at that meeting to					
	establish arrangements for a People Committee as one of the eight					
	Committees and three Advisory Groups that reports to the Board."					
	It should be noted that until February 2023 there was a BCUHB					
	"Partnerships, People and Population Health Committee" In the new					
	arrangements those responsibilities are now with:					
	The People Committee					
	The Planning, Population Health and Partnerships Committee					
	A proposed Terms of Reference has been further developed in this					
	paper using the following approach:					
	- Utilising the outline remit of each Committee agreed on 28					
	September Health Board.					
	- Considering and adopting the recommendations from the Office					
	of the Board Secretary Review in 2023.					
	- A review of Welsh Health Boards' Terms of Reference.					
	- A review of the Standing Orders for Health Boards					
	 A review of Committee Handbooks – provided by Welsh 					
	Government.					
	These prepaged Terms of Deference for the Deside Convertities have					
	These proposed Terms of Reference for the People Committee have					
	been developed and were noted and considered at the Audit					
	Committee on 16 November 2023. At the Health Board on 30					
	November 2023 it was confirmed that the draft Terms of Reference					

	would be develop	ed in 1	more detail v	with the Chair	and	Executive Lead				
	for the Committee		•							
	January 2024. Ti					-				
	changes that may be agreed at that meeting as the deadline for									
	publishing reports is the 5 th January 2024.									
	The Acting Board Secretary would like to thank the Chair and Executive									
	Lead for their help in developing the Terms of Reference and is asking									
	the Committee to	reviev	v and endors	se the draft T	erms	of Reference				
	ahead of being p	resente	ed to the Bo	ard to conside	er for	approval on 25				
	January 2024.									
Argymhellion:	The Committee is	saske	d to:							
Recommendations:	Daviawa	a d E a	dence the d		Defe					
Recommendations.	• Review a	na En	dorse the di	raft Terms of	Relei	ence				
Arweinydd										
Gweithredol:	Phil Meakin - Acti	ng Bo	ard Secretar	гy						
Executive Lead:										
Awdur yr Adroddiadu	Phil Meakin – Acting Board Secretary Support by:									
Awdur yr Adroddiad:		es – S	Special Meas	sures Project	Mana	ager				
Report Authors:				ad of Corpora						
Pwrpas yr	 Diane Dav I'w Nodi 	/ies –		iovernance M fynu arno	-	er Am sicrwydd				
adroddiad:	For Noting			ecision		For Assurance				
Purpose of report:	\boxtimes		[\boxtimes				
Lefel sicrwydd:	Arwyddocaol	D	erbyniol	Rhanno		Dim Sicrwydd				
-	Significant		ceptable	Partial		No Assurance				
Assurance level:	Lefel uchel o	Lefel av	ffredinol o	Rhywfaint o		Dim hyder/tystiolaeth o				
	hyder/tystiolaeth o ran darparu'r mecanweithiau	hyder/ty	rstiolaeth o ran 'r mecanweithiau	hyder/tystiolaeth o darparu'r mecanw		ran y ddarpariaeth				
	/ amcanion presennol		ion presennol	/ amcanion preser		No confidence / evidence in delivery				
	High level of confidence/evidence in delivery of existing	evidenc	l confidence / e in delivery of mechanisms /	Some confidence . evidence in delive existing mechanis	ry of					
	mechanisms/objectives	objectiv		objectives	1137					
Cyfiawnhad dros y gyf Sicrwydd' wedi'i nodi terfyn amser ar gyfer o	uchod, nodwch ga cyflawni hyn:	amau	i gyflawni s	icrwydd 'De	rbyni	ol' uchod, a'r				
Justification for the ab indicated above, pleas the timeframe for achi	se indicate steps t	-								
Cyswllt ag Amcan/Am	•		This work links to all strategic objectives of the Health Board as corporate Governance is a							
Link to Strategic Object Goblygiadau rheoleidd			key enable	er for them.						


Regulatory and legal implications:	The Health Board is required to act according to its Standing Orders. This report contains information to allow the Health Board to conform to this. It is essential that the Board has robust arrangements in place for Corporate Governance and failure to do so could have legal implications for the Health Board.
Yn unol â WP7, a oedd EqIA yn angenrheidiol ac a gafodd ei gynnal?	This is not applicable for this report.
In accordance with WP7 has an EqIA been identified as necessary and undertaken?	
Yn unol â WP68, a oedd SEIA yn angenrheidiol ac a gafodd ei gynnal?	This is not applicable for this report.
In accordance with WP68, has an SEIA identified as necessary been undertaken?	
Manylion am risgiau sy'n gysylltiedig â phwnc a chwmpas y papur hwn, gan gynnwys risgiau newydd (croesgyfeirio at y BAF a'r CRR)	The nature of this paper has an impact on the way Corporate Governance is reported and managed in the Health Board. Risks related to Workforce are significant and the development of this Commitee will support a review of these
Details of risks associated with the subject and scope of this paper, including new risks(cross reference to the BAF and CRR)	risks as part of its cycle of Business.
Goblygiadau ariannol o ganlyniad i roi'r argymhellion ar waith	The effective management of Governance has the potential to leverage a positive financial dividend for the Health Board through better integration of risk management into business
Financial implications as a result of implementing the recommendations	planning, decision-making and in shaping how care is delivered to our patients thus leading to enhanced quality and less waste
Goblygiadau gweithlu o ganlyniad i roi'r argymhellion ar waith	Failure to have effective Corporate Governance can impact adversely on the workforce.
<i>Workforce implications as a result of implementing the recommendations</i>	The development of a People Committee will strengthen arrangements for workforce related matters
Adborth, ymateb a chrynodeb dilynol ar ôl ymgynghori	An iteration of this paper will be received at the Health Board on 25 January 2024.
Feedback, response, and follow up summary following consultation	
Cysylltiadau â risgiau BAF: (neu gysylltiadau â'r Gofrestr Risg Gorfforaethol)	The nature of this paper, in particular the Section on Corporate Risk Register has an impact on the way the Board Assurance Framework will be reported and managed in the Health Board after the Development of a
<i>Links to BAF risks:</i> (or links to the Corporate Risk Register)	Risk Management Framework.
Rheswm dros gyflwyno adroddiad i fwrdd cyfrinachol (lle bo'n berthnasol)	

Reason for submission of report to Not applicable confidential board (where relevant) Not applicable							
Next Steps:							
 The Acting Board Secretary to take the final draft of the Terms of Reference for formal approval at the Health Board on 25 January 2024. 							
List of Appendices:							
Appendix 1 – Draft Terms of Reference for the People Committee.							



PEOPLE COMMITTEE

TERMS OF REFERENCE



Version	Issued to	Date	Comments
v0.01 Draft	Audit Committee	16/11/23	Developed as a first draft for review with
			Committee Chairs and Lead Executives
v0.02 Draft	ToR meeting with Committee	08/01/24	Updated after a desktop review and draft agreed
	Chair and Executive Lead		for the People Committee to be held on 12/01/24

1) Introduction

1.1 The Betsi Cadwaladr University Health Board (BCUHB) shall establish a Committee to be known as the People Committee. The Committee is an independent Committee of the Board and has no executive powers, other than those specifically delegated in these terms of reference. The detailed operating arrangements in respect of this Committee are set out below.

2) Purpose

The purpose of the People Committee is to:

- 2.1 To provide assurance to the Board on compliance with legislation, guidance and best practice around the People and Organisational Development (OD) agenda.
- 2.2 To provide assurance to the Board on the implementation of the Health Board's People and OD Strategy, and the all-Wales Health & Social Care Workforce Strategy, ensuring these are consistent with the Board's overall strategic direction and with any requirements and standards set for NHS bodies in Wales.
- 2.3 To provide assurance to the Board on the organisation's ability to create and manage strong, high performance, organisational culture arrangements.
- 2.4 To receive assurance on delivery against all relevant People Planning Objectives.
- 2.5 To provide assurance that the organisation is discharging its functions and meeting its responsibilities with regard to the research and innovation activity carried out within the Health Board.
- 2.6 Provide assurance that there are appropriate arrangements to ensure education and commissioning meets future workforce needs.
- 2.7 Delegated powers to consider reports on the position in regard to whistleblowing and Speaking Out Safely.
- 2.8 To seek assurance on the management of principle risks within the Board Assurance Framework (BAF) and Corporate Risk Register (CRR) allocated to the Committee and provide assurance to the Board that risks are being managed effectively and report any areas of significant concern.
- 2.9 Oversight, delivery and monitoring of Health and Safety strategies, planning, policies, performance and regulatory compliance.

3) Responsibilities of the People Committee

The People Committee shall provide advice, assurance and support to the Board in ensuring the provision of high quality, safe healthcare for its citizens, as follows:

- 3.1 To provide assurance to the Board on compliance with legislation, guidance and best practice around People and OD agenda, learning from work undertaken nationally and internationally, ensuring the Health Board is recognised as a leader in this field.
- 3.2 To provide assurance to the Board on the implementation of the Health Board's People and OD Strategy, and the all-Wales Health & Social Care Workforce Strategy, ensuring these are consistent with the Board's overall strategic direction and with any requirements and standards set for NHS bodies in Wales.
- 3.3 To provide assurance to the Board on the organisation's ability to create and manage strong, high performance, organisational culture arrangements.
- 3.4 To provide assurance that the organisation is discharging its functions and meeting its responsibilities with regard to the research and innovation activity carried out within the Health Board.
- 3.5 Provide assurance that there are appropriate arrangements to ensure education and commissioning meets future workforce needs.
- 3.6 To recommend acceptance of risks that cannot be brought within the Health Board's risk appetite/tolerance to the Board through the Committee Update Report.
- 3.7 To receive assurance through any Committee Update Reports (that may be in existence or developed) and other management group reports that risks relating to their areas are being effectively managed across the whole of the Health Board's activities (including for hosted services and through partnerships and Joint Committees as appropriate).
- 3.8 Assure the Board in relation to its compliance with relevant national practice, mandatory guidance, healthcare standards and duties, including Duty of Quality, Duty of Candour, Quality Standards and Quality Management ensuring the Board is supported to make strategic decisions through a quality lens.

4) Membership

4.1 Formal membership of the Committee shall comprise of the following:

MEMBERS
Independent Member (Chair)
2 x Independent Members (one of whom will be designated as Vice Chair)

4.2 The following should attend Committee meetings:

IN ATTENDANCE

Executive Director of People Services (Executive Lead)

Chief Executive

Executive Director of Operations

Other Attendees

Other Executive Directors as required by the Chair

Other Senior Managers as required by the Chair

- 4.3 The membership of the Committee reflected above shall be determined by the Board, based on the recommendation of the Health Board Chair, taking into account the balance of skills and expertise necessary to deliver the Committee's remit, and subject to any specific requirements or directions made by the Welsh Government.
- 4.4 Membership of the Committee will be reviewed on an annual basis.

5) Quorum and Attendance

- 5.1 A quorum shall consist of no less than two of the membership and must include as a minimum the Chair or Vice Chair of the Committee, together with a third of the In Attendance members.
- 5.2 Any senior officer of the Health Board or partner organisation may, where appropriate, be invited to attend, for either all or part of a meeting, to assist with discussions on a particular matter.
- 5.3 The Committee may also co-opt additional independent external 'experts' from outside the organisation to provide specialist skills.
- 5.4 Should any 'in attendance' officer member be unavailable to attend, they may nominate a deputy to attend in their place, subject to the agreement of the Chair.
- 5.5 The Committee may ask any or all of those who normally attend but who are not members to withdraw to facilitate open and frank discussion of particular matters.

6) Agenda and Papers

- 6.1 The Committee Secretary is to hold an agenda setting meeting with the Chair and/or Vice Chair and the Executive Lead (Executive Director of People Services) at least six weeks before the meeting date.
- 6.2 The agenda will be based around the Committee work plan, identified risks, matters arising from previous meetings, issues emerging throughout the year, and requests from Committee members. Following approval, the agenda and timetable for request of papers will be circulated to all Committee members.
- 6.3 All papers must be approved by the Executive Lead.
- 6.4 The agenda and papers will be distributed/published seven days in advance of the meeting.
- 6.5 A draft table of actions will be issued within two days of the meeting. The minutes and table of actions will be circulated to the Executive Lead within seven days to check the accuracy, prior to sending to Members to review within the next seven days.

6.6 Members must forward amendments to the Committee Secretary within the next seven days. The Committee Secretary will then forward the final version to the Committee Chair for final review.

7) In Committee

7.1 The Committee can operate with an In Committee function to receive updates on the management of sensitive and/or confidential information.

8) Meetings

- 8.1 The Committee will meet bi-monthly and an annual schedule of meetings will be determined by the corporate calendar.
- 8.2 The Committee may be convened at short notice if requested by the Chair.
- 8.3 Any additional meetings will be arranged under exceptional circumstance and shall be determined by the Chair of the Committee in discussion with the Lead Director.
- 8.4 The Committee may, subject to the approval of the Health Board, establish groups to carry out on its behalf specific aspects of Committee Business.
- 8.5 Meetings may be held in person where it is safe to do so or by video-conferencing and similar technology.
- 8.6 The Committee Secretary shall be determined by the Board Secretary.

9) Reporting

- 9.1 The Committee, through its Chair and members, shall work closely with the other Committees to provide advice and assurance to the Board through joint planning and coordination of Board and Committee business including sharing of information.
- 9.2 The Committee Chair, supported by the Committee Secretary, shall:
 - Report formally, regularly and on a timely basis to the Board on the Committee's activities.
 - Bring to the Board's specific attention any significant matter under consideration by the Committee.
 - Ensure appropriate escalation arrangements are in place to alert the Health Board's Chair, Chief Executive and/or Chairs of other relevant Committee, of any urgent/critical matters that may affect the operation and/or reputation of the Health Board.
- 9.3 The Committee will undertake an annual review on the effectiveness of its arrangements and responsibilities. The Office of the Board Secretary will lead this review.

10) Accountability, Responsbility and Authority

- 10.1 Although the Board has delegated authority to the Committee for the exercise of certain functions, as set out in these Terms of Reference, it retains overall responsibility and accountability for ensuring the quality and safety of healthcare for its citizens through the effective governance of the organisation.
- 10.2 The Committee is directly accountable to the Board for its performance in exercising the functions set out in these terms of reference.
- 10.3 The requirements for the conduct of business as set out in the Health Board's Standing Orders are equally applicable to the operation of the Committee.
- 10.4 The Committee shall embed the corporate goals and priorities, e.g. equality and human rights through the conduct of its business, and in doing and transacting its business shall seek assurance that adequate consideration has been given to the sustainable development principle and in meeting the requirements of the Well-being of Future Generations Act.

11) Review Date

11.1 These Terms of Reference and operating arrangements shall be reviewed on at least an annual basis by the Committee for approval by the Board.



Teitl adroddiad:	Developing a Cycle of Business for the People Committee
Report title:	
Adrodd i:	
	People Committee
Report to:	
Dyddiad y Cyfarfod:	Friday 12 January 2024
Date of Meeting:	Friday, 12 January 2024
Crynodeb	The purpose of this report is for the Committee to discuss a forward
Gweithredol:	
	work programme for the People Committee and consider the
Executive Summary:	development of a Cycle of Business for the People Committee.
	On 16 November 2023, the Audit Committee noted, considered and
	received assurance on how Committee Workplans were being
	developed to support the effective Governance of the Committees. It
	was highlighted that initial work programmes for the three Committees
	that had not yet been established/re-established would need to be
	developed and this included the establishment of a People
	Committee . It was agreed that these work programmes would need a
	longer lead time to align with the recruitment of Independent Members
	through the Public Appointment process.
	The Acting Board Secretary and Executive Lead would like to
	emphasise to the Committee the value in having a discussion in
	this meeting about the forward work programme and what the
	Committee wishes to achieve. For example, what are the big
	issues? what can it influence? how can it help inform the Board?
	This will then further inform the Committee Cycle of Business.
	The development of the Draft Cycle of Business in Appendix 1 follows a
	format with a number of categories that we will use in all Committee
	cycles of business. Those being:
	1. Opening Business
	2. Strategic Priorities
	3. Issues Related to Significant Risk
	4. Assurance (routine matters for consideration/assurance)

	 The content of the Draft cycles of business were undertaken by the following method: 1. Reviewing the previous Committees Cycle of Business that were in place prior to February 2023 in the context of the new 								
	Terms of Reference. 2. Reviewing other similar Welsh Health Board's Terms of								
		·		ness for ben					
	3. Meeting w		-			-			
				the first Com					
	This discussion w the Acting Board		•	ief Executive	e with	the support of			
Argymhellion:	The Committee is asked to:								
Recommendations:	 Discuss the forward programme for this Committee. Consider a Cycle of Business for the next 12 months 								
Arweinydd Gweithredol:	Phil Meakin - Acting Board Secretary								
Executive Lead:	Phil Moakin Acting Roard Socratory								
Awdur yr Adroddiad:	Phil Meakin – Acting Board Secretary Support by:								
			•	ures Project d of Corpora		•			
Report Authors:				overnance M					
Pwrpas yr adroddiad: <i>Purpose of report:</i>	I'w NodiI Benderfynu arnoAm sicrwyddFor NotingFor DecisionFor AssuranceIIII								
Lefel sicrwydd:	Arwyddocaol		erbyniol	Rhanno		Dim Sicrwydd No Assurance			
Assurance level:	Significant □	AC	ceptable ⊠	Partial					
	Lefel uchel o hyder/tystiolaeth o ran darparu'r mecanweithiau / amcanion presennol	hyder/ty darparu	ffredinol o stiolaeth o ran 'r mecanweithiau ion presennol	Rhywfaint o hyder/tystiolaeth o darparu'r mecanw / amcanion preser	eithiau	Dim hyder/tystiolaeth o ran y ddarpariaeth <i>No confidence / evidence</i>			
	High level of confidence/evidence in delivery of existing mechanisms/objectives	l of General confidence / Some confidence / evidence in delivery of existing mechanisms / existing mechanisms / in delivery of existing mechanisms /							

Cyfiawnhad dros y gyfradd sicrwydd uchod. Lle bo sicrwydd 'Rhannol' neu 'Dim Sicrwydd' wedi'i nodi uchod, nodwch gamau i gyflawni sicrwydd 'Derbyniol' uchod, a'r terfyn amser ar gyfer cyflawni hyn:

Justification for the above assurance rating. Where 'Partial' or 'No' assurance has been indicated above, please indicate steps to achieve 'Acceptable' assurance or above, and the timeframe for achieving this:

Cyswllt ag Amcan/Amcanion Strategol:	This work links to all strategic objectives of the Health Board as corporate Governance is a
Link to Strategic Objective(s):	key enabler for them.
Goblygiadau rheoleiddio a lleol: Regulatory and legal implications:	The Health Board is required to act according to its Standing Orders. This report contains information to allow the Health Board to conform to this. It is essential that the Board has robust
	arrangements in place for Corporate Governance, as failure to do so could have legal implications for the Health Board.
Yn unol â WP7, a oedd EqIA yn angenrheidiol ac a gafodd ei gynnal?	This is not applicable for this report
angenmendor ac a galodd ei gynnai?	This is not applicable for this report.
In accordance with WP7 has an EqIA been identified as necessary and undertaken?	
Yn unol â WP68, a oedd SEIA yn angenrheidiol ac a gafodd ei gynnal?	This is not applicable for this report.
In accordance with WP68, has an SEIA identified as necessary been undertaken?	
Manylion am risgiau sy'n gysylltiedig â phwnc a chwmpas y papur hwn, gan gynnwys risgiau newydd (croesgyfeirio at y BAF a'r CRR) Details of risks associated with the subject	The nature of this paper has an impact on the way Corporate Governance is reported and managed in the Health Board. Workforce risks are in both the BAF and CRR and the development of this Commitee will help oversee the management of these risks
and scope of this paper, including new risks(cross reference to the BAF and CRR)	through a Committee.
Goblygiadau ariannol o ganlyniad i roi'r argymhellion ar waith Financial implications as a result of implementing the recommendations	The effective and efficient mitigation and management of Corporate Governance has the potential to leverage a positive financial dividend for the Health Board through better integration of risk management into business planning, decision-making and in shaping how care is delivered to our patients thus leading to enhanced quality and less waste
Goblygiadau gweithlu o ganlyniad i roi'r argymhellion ar waith Workforce implications as a result of implementing the recommendations	Failure to capture, assess and mitigate Corporate Governance can impact adversely on the workforce.
Adborth, ymateb a chrynodeb dilynol ar ôl ymgynghori Feedback, response, and follow up summary following consultation	An iteration of this paper will be received at the Health Board on 25 January 2024.
Cysylltiadau â risgiau BAF: (neu gysylltiadau â'r Gofrestr Risg Gorfforaethol)	The nature of this paper, inparticular the Section on Corporate Risk Register has an impact on the way the Board Assurance Framework will be reported and managed in

Links to BAF risks:	the Health Board after the Development of a						
(or links to the Corporate Risk Register)	Risk Management Framework.						
Rheswm dros gyflwyno adroddiad i fwrdd cyfrinachol (lle bo'n berthnasol)							
Reason for submission of report to	Not applicable						
confidential board (where relevant)							
 Next Steps: The Acting Board Secretary will work with the Executive Lead of the Committee to adjust the detailed Cycle of Business to reflect the discussion that is had in the meeting on the forward work programme. The Acting Board Secretary to take a draft Cycle of Business for noting at the Health Board on 25 January 2024. 							
List of Appendices:							
Appendix 1 – Draft Cycle of Business People Co	mmittee						

		-	Committe April 2024	-					Bwrdd Iechyd Prifysgol Betsi Cadwaladr University Health Board
Item of Business	Purpose	Lead	April 2024	June 2024	August 2024	October 2024	December 2024	February 2025	Notes
			Opening	g Busines	5	,	1		1
Apologies			\checkmark	 ✓ 	✓	✓	✓	\checkmark	
Declarations of Interest			✓	✓	 ✓ 	✓	~	√	
Minutes from the previous meeting			✓	~	~	~	~	~	
Matters arising & Table of actions			✓	~	✓	✓	~	√	
Report of the Chair: • Chair's action • Feedback from Board	This can be used as a placeholder if required (by exception)		~	×	√	~	√	✓	
Notification of matters referred from other Committees			#	#	#	#	#	#	
			Strategi	c Prioritie	S		·		
Annual Review of People & OD Strategy		Executive Director of People Services				√			Suggest include in People report
	·	lss	sues Relate	ed to Key	Risks	'	·		·
Board Assurance Framework related to Committee		Board Secretary	✓	✓	✓	✓	~	~	
Corporate Risk Register related to Committee		Board Secretary	✓	~	v	~	~	\checkmark	

People Committee Cycle of Business (April 2024 – March 2025)									Bwrdd Iechyd Prifysgol Betsi Cadwaladr University Health Board	
Item of Business	Purpose	Lead	April 2024	June 2024	August 2024	October 2024	December 2024	February 2025	Notes	
Placeholder for any agenda items deriving from the BAF & CRR		Board Secretary	#	#	#	#	#	#		
			For As	ssurance						
People Report		Executive Director of People Services	~	✓	√	✓	~	✓		
Speak Out Safely Report		Executive Director of People Services				√			Suggest this is included as appendix to People report above	
Corporate Health at Work		Executive Director of People Services			√			✓	Suggest this is included as appendix to People report above	
Equality Annual Report		Executive Director of People Services			✓					
Health and Safety report		Executive Director of People Services / CEO	~	×	v	~	V	v		
Organisational Development report		Executive Director of People Services	~	✓	✓	✓ 	~	✓	Review regularity after 6 months	
Education and Training report		Executive Director of People Services		√		✓		✓		
Research and Innovation report		Executive Director	•		√		 ✓ 			

People Committee Cycle of Business (April 2024 – March 2025)								Bwrdd Iechyd Prifysgol Betsi Cadwaladr University Health Board		
Item of Business	Purpose	Lead	April 2024	June 2024	August 2024	October 2024	December 2024	February 2025	Notes	
		Therapies and								
		Health Sciences								
Professional Registration		Clinical Executive							To be discussed	
monitoring report		Directors /								
		Executive								
		Director of								
		People Services								
Workforce (People)		Executive								
Annual Report		Director of								
		People Services								
Chairs Assurance Reports										
from Strategic and										
Tactical Delivery Groups:										
Strategic Equalities Forum										
Committee Annual		Secretariat						✓		
Report to Audit										
Committee										
Review Committee Terms		Secretariat	\checkmark					✓		
of Reference & Cycle of										
Business										
			Closing	Business						
Agree Items for referral to			✓	✓	✓	✓	✓	~		
Board / other										
Committees										
Review of Risks			✓	✓	✓	✓	✓	✓		
highlighted in the										
meeting for referral to										
Risk Management Group										

People Committee Cycle of Business (April 2024 – March 2025)										
Item of Business	Purpose	Lead	April 2024	June 2024	August 2024	October 2024	December 2024	February 2025	Notes	
Agree items for Chairs Assurance Report			~	•	✓	√	~	~		
Summary of Private Business to be reported in Public			#	#	#	#	#	#		
Review of Meeting Effectiveness			~	~	~	~	~	√		
Date of Next Meeting			~	~	~	~	~	~		
Part B Rolling Programme of Ad-hoc Items										
ТВС										
ТВС										